Fourth-gen Mini gets a soft-top variant► Three petrol engines, but no manual► Still as fun and stylish as ever? Despite being a country renowned for such bleak weather, the UK is one of the biggest ...

Novo Nordisk (NVO) reported better-than-expected ... Shares of the Danish drugmaker rose ~4% in European trading, while Eli Lilly (LLY), its main rival in the obesity market, added ~2% in the ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

Novo Nordisk A/S today announced 2024 earnings ... If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare ...

Good day, and thank you for standing by. Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded.

Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 billion. On Wednesday, Novo Nordisk A/S NVO ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024 ... 5:14 PM UTC · Updated ago Technologycategory AMD's $4.9 bln ZT Systems deal faces EU antitrust decision by ...

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

Dividend Increase: 21% increase to DKK11.40 per share. Share Buyback Program: DKK20 billion concluded. Novo Nordisk AS (NYSE:NVO) reported a strong 26% sales growth and 26% operating profit growth for ...